Le Lézard
Classified in: Health
Subject: TRI

Werfen Announces CE Mark for Aptiva CTD Essential Reagent


SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- Werfen, a worldwide leader in specialized diagnostics for autoimmune disease, is pleased to announce the CE Mark of Aptiva® CTD Essential Reagent for use on the Aptiva® system. Aptiva is a fully automated multi-analyte system that represents the next generation of high throughput instruments for the clinical laboratory. 

Aptiva utilizes a particle-based multi-analyte technology (PMAT)

Aptiva addresses many health economic shortcomings in the autoimmune laboratory. Existing systems provide a limited number of analytes that leave a significant seronegative gap found in many disease states. Aptiva will cover several autoimmune disease states and has over 60 analytes in various stages of advanced development. These analytes have the potential to help clinicians close the seronegative gap and improve diagnostic confidence.

Aptiva also provides economic benefits for the laboratory. The 150-sample rack capacity and a 6.5-hour consumable walkaway time delivers new levels of workflow efficiencies by reducing the number of daily interventions. Aptiva uses a digital particle-based multi-analyte technology (PMAT), that processes multiple analytes simultaneously from a patient sample. PMAT enables Aptiva CTD Essential Reagent to deliver up to 660 results per hour and allows the laboratory to complete its test volume with minimal hands-on time.

"Aptiva CTD Essential with its unique biomarker composition and high level of analytical and clinical performance represents a breakthrough that fundamentally enhances the utility of diagnostic testing in the autoimmune laboratory," said Michael Mahler, PhD., Vice President of Research and Development at Werfen. "Aptiva CTD Essential will deliver expanded information to clinicians for management of patients with autoimmune diseases."

For more information about Aptiva, please contact your local Werfen Representative.

About Werfen

Werfen (www.werfen.com), founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company's business lines include Hemostasis, Acute Care Diagnostics (ACD), Autoimmunity, and Original Equipment Manufacturing (OEM). Werfen's Hemostasis portfolio includes ACL TOP® Family 50 Series and ACL TOP Family Hemostasis Testing Systems, ACL AcuStar® system, ACL Elite® systems, HemoCelltm Specialized Lab Automation, HemoHubtm Intelligent Data Manager, along with the comprehensive line of HemosIL® assays. The ACD portfolio includes the GEM® Premiertm 5000 system with Intelligent Quality Management 2 (iQM®2), GEM Premier 3500 system with iQM, GEM Premier ChemSTATtm system, GEMweb® Plus Custom Connectivity, ROTEM® viscoelastic testing systems, Hemochrontm systems, VerifyNowtm platelet function testing system, and Avoximetertm CO-Oximeters. The Autoimmunity portfolio includes Aptiva®, BIO-FLASH®, NOVA View®, AUTOLoader and QUANTA-Lyser® 3000 systems, and QUANTA Link® data management solutions. The OEM business line offers services for end-to-end development and manufacturing of customized immunoassays and biomaterials for diagnostic companies.

The Werfen logo is a trademark of Werfen. GEM, Premier, GEM Premier ChemSTAT, GEMweb, iQM, ChemSTAT, HemosIL, ACL, ACL TOP, ACL Elite, ACL AcuStar, ReadiPlasTin, RecombiPlasTin, SynthASil, SynthAFax, ROTEM, Hemochron, VerifyNow and Avoximeter are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or its parent company. Aptiva, QUANTA-Lyser, QUANTA Lite, QUANTA Link, QUANTA Flash, NOVA View, NOVA Lite are registered trademarks of Inova Diagnostics, Inc., a part of Werfen, as the legal manufacturer. BIO-FLASH is a registered trademark of Biokit S.A. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.

Werfen logo

Photo - https://mma.prnewswire.com/media/1233083/Inova_Aptiva.jpg

Logo - https://mma.prnewswire.com/media/1698025/AF_WERFEN_BLUE_POS_RGB_Logo.jpg

 


These press releases may also interest you

at 10:34
ReferralMD, a leader in healthcare technology solutions, is excited to announce the expansion of its Digital Front Door offering using the latest innovation in conversational AI. The Patient Registration & Intake Solution, powered...

at 10:30
Biomarkers Market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029 according to a new report by MarketsandMarketstm. The growing...

at 10:30
The national "Seize the Awkward" campaign premiered a new digital content series today starring and directed by actress, activist, and creator Nia Sioux. The "Capture the Convo" series marks the former "Dance Moms" star and executive producer's debut...

at 10:30
Medical Facilities Corporation ("Medical Facilities" or "MFC") will release its first quarter 2024 financial results prior to market open on Thursday, May 9, 2024. MFC's financial statements and management's discussion and analysis for the...

at 10:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 10:30
Trella Health, the leader in HME and Infusion growth and productivity solutions, announces the recent release of claim and patient counts within its Marketscape Insights platform. "The patient...



News published on and distributed by: